Relay Therapeutics: Oppenheimer Raises Rating to "Outperform" and Sees 80% Price Potential!

Relay Therapeutics (RLAY) focuses on the so-called "Dynamo platform." While traditional drug discovery methods often view proteins as static structures, Relay integrates computational simulations and experimental data to analyze protein movement. This approach aims to make previously considered inaccessible target structures vulnerable or to drastically increase the selectivity of drugs. Current Status of the Clinical Pipeline The company's pipeline is currently dominated by two main programs. The most advanced program is Lirafugratinib (RLY-4008),...